Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRO-HEP study of telaprevir + ribavirin for acute hepatitis C in HIV-infected men
NL-OMON20763Not yet recruiting
- Sponsor
- University Medical Center Utrecht
- Start
- Jun 2012
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of telaprevir and ribavirin in hepatitis C virus infection and human immunodeficiency virus infection (HIV), sponsored by University Medical Center Utrecht. Primary endpoint: Sustained virologic response. Planned start Jun 2012; status: not yet recruiting.
02
Drugs
telaprevirribavirin
03
Conditions
hepatitis C virus infectionhuman immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NL-OMON20763.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON20763.